Work

Abstract B036: Complement C3 inhibition as a novel immunotherapy strategy in recurrent ovarian cancer with malignant effusions: Interim results from a phase 2 trial of pegcetacoplan

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.ovarian25-b036

Authors: Emese Zsiros, Thejaswini Giridharan, ANM Nazmul H. Khan, Sora Suzuki, Peter Frederick, Kathrine LaVigne Mager, Karen McLean, Nicole Gaulin, Audrey Rawleigh, Suzanne M. Hess, Celia DeJohn, Maximilian Smidt, Brian A. Joughin, Martin Kolev, Pascal Deschatelets, Michael B. Yaffe, Brahm H. Segal

Institutions: Roswell Park Comprehensive Cancer Center, University of Michigan, Moffitt Cancer Center, Massachusetts Institute of Technology, Apellis Pharmaceuticals (United States)

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4414349298

Cites:

Cited by:

Related to: